Rybelsus is a once-daily semaglutide tablet used to treat type 2 diabetes. In the UAE, pharmacies list the 3 mg, 7 mg and 14 mg strengths on prescription. It is taken in the morning on an empty stomach, at least 30 minutes before food, drink or other medications. Rybelsus can lead to weight loss, but it is licensed for type 2 diabetes, not weight management. The Wegovy pill is the semaglutide tablet licensed for weight management.
- The US prescribing information starts Rybelsus at 3 mg once daily for 30 days, a starting dose that is not intended to control blood sugar.
- After the first month, the dose is 7 mg, and your endocrinologist may increase it to 14 mg if more blood sugar control is needed.
- In a 26-week trial in adults with type 2 diabetes, HbA1c fell by around 1.2 percentage points on 7 mg and 1.4 on 14 mg, against 0.3 on placebo.
- In the trials, nausea was reported by 11% of patients taking 7 mg and 20% taking 14 mg, against 6% taking a placebo.
- Taking Rybelsus with insulin or a sulfonylurea can increase the risk of low blood sugar, so your endocrinologist may lower the dose of those medications.
- The prescribing information advises stopping Rybelsus at least two months before a planned pregnancy.
- Rybelsus is not licensed for weight loss, and the semaglutide tablet approved for weight management in the UAE is the Wegovy pill.
Rybelsus is made by Novo Nordisk, which also makes Ozempic and the Wegovy pill. All three contain semaglutide, at different doses and for different uses.
What is Rybelsus?
Rybelsus is a GLP-1 receptor agonist. It acts on the same receptor as GLP-1, a hormone the gut releases after eating. The StatPearls clinical reference on GLP-1 receptor agonists describes how these medications help the body release insulin when blood sugar rises. They also reduce the release of glucagon, a hormone that raises blood sugar, and slow the emptying of the stomach.
Rybelsus is approved, alongside diet and exercise, to improve blood sugar control in adults with type 2 diabetes. The US prescribing information for Rybelsus, revised in January 2026, also lists a lower risk of major cardiovascular events, such as heart attack and stroke, in adults with type 2 diabetes at high risk.
How do you take Rybelsus?
The prescribing information sets out the following morning routine:
- In the morning, on an empty stomach
- One tablet, swallowed whole, without splitting, crushing or chewing
- No more than half a cup (120 mL) of plain water
- Nothing to eat or drink, and no other tablets, for at least 30 minutes
- No more than one tablet a day
These steps help semaglutide to be absorbed from the tablet. The Wegovy pill follows the same rule, and our guide to starting the Wegovy pill explains how food and drink can reduce absorption of the same active ingredient.
Rybelsus doses: 3 mg, 7 mg and 14 mg
Rybelsus comes in three doses, and the prescribing information sets out how they are used:
| Dose | When | Purpose |
|---|---|---|
| 3 mg once daily | Days 1 to 30 | A starting dose that is not intended to control blood sugar |
| 7 mg once daily | From day 31 | The first maintenance dose |
| 14 mg once daily | After at least 30 days on 7 mg, if needed | A higher dose when more blood sugar control is needed |
Your endocrinologist will decide with you whether to stay on 7 mg or move to 14 mg, based on your blood sugar and how well you tolerate the medication. If you miss a dose, the prescribing information advises skipping it and taking the next tablet the following day.
How well does Rybelsus lower blood sugar?
To see whether Rybelsus is helping your diabetes, your doctor will monitor your HbA1c. HbA1c, the test used most often, reflects your average blood sugar over approximately the previous three months. In a 26-week clinical trial of adults whose type 2 diabetes was not controlled by diet and exercise alone, HbA1c fell by around 1.2 percentage points on 7 mg and 1.4 on 14 mg. It fell by around 0.3 on placebo. Your endocrinologist re-checks your HbA1c every three to six months until your treatment is stable, then every six months once it is.
Rybelsus side effects
Digestive side effects are reported more often than others. The table below, from the prescribing information, shows the share of patients who reported each one in the clinical trials.
| Side effect | Placebo | Rybelsus 7 mg | Rybelsus 14 mg |
|---|---|---|---|
| Nausea | 6% | 11% | 20% |
| Abdominal pain | 4% | 10% | 11% |
| Diarrhoea | 4% | 9% | 10% |
| Decreased appetite | 1% | 6% | 9% |
| Vomiting | 3% | 6% | 8% |
| Constipation | 2% | 6% | 5% |
Not every patient experiences them. Side effects such as nausea or constipation can be particularly pronounced in the first few days at a new dose. They often improve as your body adjusts, although some symptoms last longer. If you experience nausea or constipation, your endocrinologist can adjust the pace of dose increases and, where needed, prescribe medication to help manage these side effects.
Taking Rybelsus with insulin or a sulfonylurea can increase the risk of low blood sugar (hypoglycemia). When Rybelsus is started, your endocrinologist may lower the dose of those medications and explain how to recognise and treat low blood sugar.
The prescribing information also notes that a rapid improvement in blood sugar has been associated with a temporary worsening of diabetic retinopathy, an eye condition. If you have retinopathy, your endocrinologist may arrange regular eye checks.
Seek medical advice immediately if you have severe stomach pain that spreads to your back and does not go away, as this can be a sign of pancreatitis. Being unable to keep fluids down and signs of a serious allergic reaction, such as swelling of the face or difficulty breathing, also need urgent medical care. Rybelsus is not used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), because semaglutide caused thyroid tumours in rodents.
Can you take Rybelsus for weight loss?
Rybelsus is not licensed for weight loss, and our endocrinologists do not prescribe it for weight loss. In the same 26-week trial, average weight fell by 2.3 kg on 7 mg and 3.7 kg on 14 mg, against 1.4 kg on placebo, in adults with type 2 diabetes.
The Emirates Drug Establishment approved the Wegovy pill, a higher-dose semaglutide tablet, for weight management in adults on 1 June 2026. In OASIS 4, a Phase 3 clinical trial in adults with obesity or overweight, patients taking the Wegovy pill lost an average of around 17% of their total body weight over 64 weeks. The two trials studied different groups of patients, so their results are not directly comparable.
Our page on weight loss pills in the UAE describes every licensed option.
Rybelsus or Ozempic: what is the difference?
Rybelsus and Ozempic contain the same active ingredient and are both approved for type 2 diabetes. Rybelsus is a daily tablet, while Ozempic is a weekly injection, available in the UAE at 0.25 mg, 0.5 mg and 1 mg.
The tablet doses are higher in milligrams because only a small share of the semaglutide in a tablet is absorbed. The prescribing information puts that share at around 0.4% to 1% for Rybelsus. It also sets out how to switch from the 0.5 mg Ozempic injection to Rybelsus 7 mg or 14 mg, one week after the last injection.
In the US, the Ozempic name is also used for a newer semaglutide tablet for type 2 diabetes, at 1.5 mg, 4 mg and 9 mg. The prescribing information states that it is not interchangeable with Rybelsus milligram for milligram. UAE pharmacies list Ozempic as an injection pen.
How much does Rybelsus cost in the UAE?
UAE pharmacies list a pack of 30 Rybelsus tablets at AED 641 for each of the 3 mg, 7 mg and 14 mg doses. Health insurance in the UAE may cover diabetes medications within your policy’s annual limits and co-payments. We recommend checking your policy schedule for your annual medicine limit, your co-payment and whether a pre-existing exclusion still applies. Our care coordinators can also help you in this process.
How Endocare treats type 2 diabetes
The International Diabetes Federation puts adult diabetes prevalence in the UAE at 20.7%, nearly double the global rate. Our endocrinologists work within the Emirates Diabetes and Endocrine Society consensus for managing type 2 diabetes, updated in 2026, alongside the international guidance this page cites.
Metformin has been the long-standing first step, and NICE guidance on type 2 diabetes now recommends SGLT2 inhibitors alongside it for many adults, particularly those with heart or kidney disease. GLP-1 receptor agonists and the newer dual agonists act on appetite and blood sugar together. Insulin is used when the body no longer produces enough of its own.
Monthly follow-up appointments can be held in person at the clinic or online. Endocare’s doctors are always available to support patients with advice.
Frequently asked questions
Do you need a prescription for Rybelsus in the UAE?
Yes. UAE pharmacies list Rybelsus as a prescription medication, so a doctor will need to assess you first. Our article on whether you can buy GLP-1 medications over the counter in the UAE explains the rules.
What should I avoid while taking Rybelsus?
Avoid food, drinks other than plain water and other tablets for at least 30 minutes after each dose. Tell your endocrinologist about any new medication, including supplements.
What happens if I miss a dose of Rybelsus?
Skip the missed dose and take your next tablet the following day, as the prescribing information advises. Do not take two tablets to make up for it.
Can I take two 7 mg tablets instead of one 14 mg tablet?
No. The prescribing information states that no more than one tablet should be taken a day. The 14 mg dose is a single 14 mg tablet.
Can I take Rybelsus if I fast during Ramadan?
For many patients, it may be possible, after a review with your endocrinologist four to six weeks before Ramadan. The practical guidelines of the International Diabetes Federation and the Diabetes and Ramadan International Alliance (IDF-DAR), first-authored by Mohamed Hassanein, a consultant at Dubai Hospital, set out how to assess the risk of fasting with diabetes. Your endocrinologist will agree the timing of your tablet with you. Our article on Ramadan and GLP-1 therapy has more general advice.
Can I take Rybelsus during pregnancy or breastfeeding?
No. Semaglutide stays in the body for weeks after the last tablet, so the prescribing information asks for a gap of at least two months between stopping Rybelsus and a planned pregnancy. Breastfeeding is not recommended while taking Rybelsus.
Patients should not decide by themselves to start a GLP-1 medication. A doctor’s review is critical to ensure the treatment is safe and appropriate for the individual.
At our Dubai clinic, your endocrinologist will assess your blood sugar control, review your medications and discuss whether Rybelsus is appropriate for you. Our page on diabetes care at Endocare explains how we manage type 2 diabetes. You can book a consultation on +971 4 285 3885 or send us a message on WhatsApp.
